BMJ 2007;335:226 (4 August), doi:10.1136/bmj.39290.503900.DB
News
Donepezil helps patients with severe Alzheimer's disease
Janice Hopkins Tanne
New York
| The first 150 words of the full text of this article appear below. |
Patients with severe Alzheimer's disease who are living at home with family care givers and are treated with donepezil stabilise or decline more slowly than patients given placebo, according to a multinational, randomised, placebo controlled trial published in Neurology (2007;69:459-69).
Donepezil was approved by the US Food and Drug Administration last year for the treatment of severe Alzheimer's disease as well as mild to moderate forms. The Canadian authorities approved its use for severe forms of the disease in June 2007.
Sandra Black, of the University of Toronto and lead author of the paper, said that North American researchers were suspicious of the decision by the UK National Institute for Health and Clinical Excellence (NICE) not to fund donepezil for patients with mild Alzheimer's disease. She said that researchers thought it might slow decline in these patients. NICE only recommends its use in patients who have moderate Alzheimer's disease. And
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article
- Full text
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Related content
Bookmark with
What's new
BMJ video
Resources
Tools
Online poll
Find out more
Services
Rapid responses for this article
There are no rapid responses for this article.Most read last week
Print issues
Student BMJ
Risk of surgery for inflammatory bowel disease: record linkage studies
What can you learn from this BMJ paper? Read Leanne Tite's Paper+
